Apollomics presents vebreltinib data at the 2024 american association for cancer research (aacr) annual meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying met-driver alterations, and effective for overcoming met-amplification dependent resistance to egfr therapies in egfr-positive non-small cell lung cancer preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying met-driver alterations, and effective for overcoming met-amplification dependent resistance to egfr therapies in egfr-positive non-small cell lung cancer
APLM Ratings Summary
APLM Quant Ranking